Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.71 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.54 |
| ▸ | CCNC | P24863 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM6B | O15054 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36668757 | 1.00 | TDP1 (0.71) | TDP1SIRT3MKNK1MKNK2CCNC | |
| SCHEMBL29682389 | 0.83 | SIRT3 (1.00) | TDP1SIRT3MKNK1MKNK2CCNC | |
| SCHEMBL1265706 | 0.83 | SIRT3 (1.00) | TDP1SIRT3MKNK1MKNK2CCNC | |
| SCHEMBL1885868 | 0.81 | TDP1 (0.52) | TDP1SIRT3CCNCCDK8KDM4C | |
| SCHEMBL115797 | 0.81 | KDM4C (0.59) | TDP1SIRT3KDM4CKDM4EALDH1A1 | |
| SCHEMBL30281300 | 0.81 | KDM4C (0.59) | TDP1SIRT3KDM4CKDM4EALDH1A1 | |
| SCHEMBL1330970 | 0.80 | TDP1 (0.67) | TDP1SIRT3MKNK1MKNK2CDK8 | |
| SCHEMBL1687197 | 0.80 | TDP1 (0.67) | TDP1SIRT3MKNK1MKNK2CDK8 | |
| SCHEMBL1967163 | 0.79 | TDP1 (0.50) | TDP1SIRT3MKNK1MKNK2CCNC | |
| SCHEMBL8485666 | 0.79 | TDP1 (0.50) | TDP1SIRT3MKNK1MKNK2CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761944-A | A kind of chrysin amide derivatives and preparation method thereof and medical usage | 武汉翼博济生生物科技有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-108779104-A | Noval chemical compound for inhibiting Nampt and the composition comprising it | 延世大学校产学协力团 | 2018-11-09 | — | — | CN | claimed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | claimed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | claimed |
| EP-2125023-A2 | SOLUBLE FORMS OF INCLUSION COMPLEXES OF HISTONE DEACETYLASE INHIBITORS AND CYCLODEXTRINS, THEIR PREPARATION PROCESSES AND USES IN THE PHARMACEUTICAL FIELD | Universita'Degli Studi di Roma "La Sapienza" (IT) | 2009-12-02 | — | — | EP | claimed |
| WO-2008090585-A2 | SOLUBLE FORMS OF INCLUSION COMPLEXES OF HISTONE DEACETYLASE INHIBITORS AND CYCLODEXTRINS, THEIR PREPARATION PROCESSES AND USES IN THE PHARMACEUTICAL FIELD | UNIVERSITÀ DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2008-07-31 | — | — | WO | claimed |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | claimed |
| WO-2005026114-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2005-03-24 | — | — | WO | claimed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3157929-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | ARES TRADING SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| EP-1456188-A1 | 7-AMINO-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1409466-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003053946-A1 | 7-AMINO-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002100844-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, FURIN, PEPD | TDP1 1771/4885SIRT3 3585/4885MKNK1 1464/4885 |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | TDP1 4107/4885SIRT3 321/4885MKNK1 635/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | TDP1 3112/4885SIRT3 4171/4885MKNK1 565/4885 |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PEPD, SERPINB1, ACE | TDP1 1533/4885SIRT3 3402/4885MKNK1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.